anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Meropenem plays a crucial role in the treatment of pulmonary exacerbations in cystic fibrosis patients, because it has activity against both P. aeruginosa and B. cepacia, two of the most problematic pathogens that are encountered in this disease. These organisms cause chronic endobronchitis with frequent exacerbations which lead to significant morbidity and premature mortality. Treatment options for pulmonary exacerbations are limited due to the high rates of resistance with currently available antibiotics and lack of development of new effective antibiotics. Therefore optimization of the dosing of meropenem, by use of extended infusion strategy, is one method to allow us to maximize the efficacy of this drug. Meropenem is a beta-lactam type antibiotic with time-dependent bactericidal activity and hence it is suitable for extended infusion dosing. The key rationale for extended infusion of beta-lactam antibiotics is to allow for optimization of pharmacodynamic target attainment of time above the minimal inhibitory concentrations (T\>MIC) to maximize bactericidal killing and optimize clinical outcomes. The use of this infusion strategy has been studied in non-cystic fibrosis patients treated primarily with piperacillin-tazobactam or meropenem for P. aeruginosa infections. The application of this strategy in cystic fibrosis patients has not been well studied, and there is no data for the treatment of B. cepacia infections. Also the pharmacokinetic characteristics of meropenem in adult cystic fibrosis patients with pulmonary exacerbation have not been previously studied. It is unclear whether or not the pharmacokinetic profile of meropenem in patients without exacerbation can be accurately extrapolated to those patients with exacerbation. The first phase of this study will, therefore, describe the pharmacokinetic profile of meropenem and the distribution of MICs for P. aeruginosa and B. cepacia in a population of adult cystic fibrosis patients with pulmonary exacerbation. The data will be used to determine an optimal extended infusion dosing strategy specifically for our patients with cystic fibrosis. The second phase of our study will provide additional data on the pharmacokinetics of meropenem in patients without active infection.

Significance of study:

This study will provide new information regarding the pharmacokinetics of meropenem in a population of cystic fibrosis patients with pulmonary exacerbation. This will allow us to apply Monte Carlo simulation to the data set with greater confidence as it directly reflects our own target population. Optimization of meropenem dosing based on pharmacodynamic profile and Monte Carlo simulation lays the groundwork for clinical efficacy studies in the future. Based on results from previous studies, optimization of meropenem dosing has the potential to produce better patient outcomes, reduce drug utilization and cost and reduce rates of resistance. These can be examined in future clinical studies.
PURPOSE:The titled preparation increasing the amount of active ingredient applied to human body, comprising a stock solution having a specific composition ratio and a ratio of the stock solution and a propellant gas in a specific range. CONSTITUTION:A composition consisting of a stock solution comprising 1.0-20wt% active ingredient (e.g. external anti-inflammatory analgesic such as methyl salicylate, etc., antitrichophytical agent such as potassium iodide, etc., drug for suppurative disease such as penicillin V, etc.), 30-70wt% ethanol and/or isopropanol, 0.5-10wt% anionic surface active agent (e.g. higher alcohol sulfuric ester salt, amino acid surface active agent, higher alcohol phosphoric ester salt, etc.) and 20-80wt% water in an amount to give 1/3-2 times as much as the alcohol and a propellant at 1.5-4.8kg/cm<2> gas pressure at 20 deg.C in a ratio to the stock solution of 1/2-1/20 is packed into an aerosol container to give an aerosol agent to be applied to human body.
The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
Uric acid is a product of purine degradation, and uric acid may have multiple physiologic roles, including the beneficial effects as an antioxidant and neuroprotector, maintenance of blood pressure during low salt ingestion, and modulation of immunity. However, overproduction of metabolic uric acid, and/or imbalance of renal uric acid secretion and reabsorption, and/or underexcretion of extrarenal uric acid, e.g. gut, will contribute to hyperuricemia, which is a common metabolic disease. Long-lasting hyperuricemia can induce the formation and deposition of monosodium urate (MSU) crystals within the joints and periarticular structures. MSU crystals further induce an acute, intensely painful, and sterile inflammation conditions named as gout by NLRP3 inflammasome-mediated cleavage of pro-IL-1β to bioactive IL-1β. Moreover, hyperuricemia and gout are associated with multiple cardiovascular and renal disorders, e.g., hypertension, myocardial infarction, stroke, obesity, hyperlipidemia, type 2 diabetes mellitus and chronic kidney disease. Although great efforts have been made by scientists of modern medicine, however, modern therapeutic strategies with a single target are difficult to exert long-term positive effects, and even some of these agents have severe adverse effects. The Chinese have used the ancient classic prescriptions of traditional Chinese medicine (TCM) to treat metabolic diseases, including gout, by multiple targets, for more than 2200 years. In this review, we discuss the current understanding of urate homeostasis, the pathogenesis of hyperuricemia and gout, and both modern medicine and TCM strategies for this commonly metabolic disorder. We hope these will provide the good references for treating hyperuricemia and gout.
BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
One LACRISERT ophthalmic insert in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes.

Individual patients may require more flexibility in the use of LACRISERT; some patients may require twice daily use for optimal results.

Clinical experience with LACRISERT indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.

LACRISERT is inserted into the inferior cul-de-sac of the eye beneath the base of the tarsus, not in apposition to the cornea, nor beneath the eyelid at the level of the tarsal plate. If not properly positioned, it will be expelled into the interpalpebral fissure, and may cause symptoms of a foreign body. Illustrated instructions are included in each package. While in the licensed practitioner's office, the patient should read the instructions, then practice insertion and removal of LACRISERT until proficiency is achieved.

NOTE: Occasionally LACRISERT is inadvertently expelled from the eye, especially in patients with shallow conjunctival fornices. The patient should be cautioned against rubbing the eye(s) containing LACRISERT, especially upon awakening, so as not to dislodge or expel the insert. If required, another LACRISERT ophthalmic insert may be inserted. If experience indicates that transient blurred vision develops in an individual patient, the patient may want to remove LACRISERT a few hours after insertion to avoid this. Another LACRISERT ophthalmic insert may be inserted if needed.

If LACRISERT causes worsening of symptoms, the patient should be instructed to inspect the conjunctival sac to make certain LACRISERT is in the proper location, deep in the inferior cul-de-sac of the eye beneath the base of the tarsus. If these symptoms persist, LACRISERT should be removed and the patient should contact the practitioner.
Safety and effectiveness of amlodipine besylate and atorvastatin calcium have not been established in geriatric populations. 

Amlodipine 

Clinical studies of amlodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40 to 60%, and a lower initial dose may be required [see Dosage and Administration (2)]. 

Atorvastatin 

Of the 39,828 patients who received atorvastatin in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Advanced age (≥65 years) is a predisposing factor for myopathy.
The incidence of pancreatic cancer has been increasing globally in recent years and dietary is a well-defined factor contributing to its carcinogenesis. In this study, we showed that in a cerulein-induced KC (Pdx1-cre; LSL-Kras G12D/+) mouse model, a fasting-mimicking diet (FMD)─comprising fasting for 3 days followed by 4 days of refeeding, repeated over three 1-week cycles─significantly retards the progression of pancreatic carcinogenesis. FMD treatment altered gut microbiota, notably boosting butyrate-producing bacteria and elevating butyric acid levels in pancreatic tissues. Furthermore, lysine pan-crotonylation (pan-Kcr) expression was markedly upregulated in pancreatic intraepithelial neoplasia (PanIN) tissues from FMD-treated mice. Treatment of normal pancreatic duct and pancreatic cancer cells with sodium butyrate also upregulated pan-Kcr expression while reducing cell proliferation. Our findings reveal the pivotal role of dietary factors in the carcinogenesis of the pancreas and support further clinical studies of FMD as an antineoplastic therapeutic measure.
At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
BACKGROUND: Persisting groin pain post total hip arthroplasty (THA) is a common and complex issue that can be difficult to diagnose and manage. Acetabular component positioning is often implicated.
AIMS AND METHODS: We used a previously well described and validated functional positioning protocol to determine if functional acetabular malpositioning was a factor in groin pain post THA and hence to determine if acetabular revision would be indicated. We compared patient-specific functional acetabular positioning to traditional CT evaluation of cup position and assessment of anterior cup overhang.
RESULTS: 39 patients with groin pain post-THA were investigated. Functional acetabular malpositioning was diagnosed in 31% (12/39). Revision THA was performed in those 12 patients, resulting in resolution of functional malpositioning (100%), with an overall accuracy of 5.6° (range 1-12), and resolution of groin pain in 67% (8/12). 33% (4/12) of the revised implants had functional positioning located outside the traditional "40/20 zone". Comparison with CT indicated that 40% (4/10) of implants with anterior overhang were well positioned, however only 50% (6/12) of functionally malpositioned implants had CT evidence of anterior cup prominence. Of the 8/12 revision patients who had resolution of their groin pain, only 1 had cup prominence.
CONCLUSIONS: This study suggests that the utilisation of a patient specific functional positioning algorithm in the analysis of persistent groin pain following THA can assist in identifying the underlying cause of pain and help to guide treatment. For a functionally malpositioned acetabulum, revision surgery offers a potential resolution of groin pain.
The inventor has discovered that (−)-hydroxycitric acid (including the forms of its various salts) is useful for treating and ameliorating cachexia, health-threatening catabolism and unhealthful weight loss, such as is characteristic of sarcopenia. The dosage will depend on factors such as the starting weight of the individual and the percentage of the calories in the diet derived from fats. On a 30 percent fat diet, an efficacious daily dosage for most individuals will be between 250 mg and 3 grams per day. It may prove beneficial to deliver the desired dosage only once per day, preferably prior to the noon meal. The weight-gain effects of HCA are compromised by the actions compounds such as caffeine and ephedrine, hence these should be avoided. Due to the biphasic characteristics of HCA, there is an obvious overlap between dosages that can lead to weight gain and the higher dosages that can lead to weight loss in those who are above their ideal body weights. There is little or no evidence that HCA ingested even in quite large amounts causes significant weight loss in individuals who are at or below their idea weights or exhibit a body mass index (BMI) at or below 20. It is to be expected that dosage will need to be matched to the current state of a given individual suffering from cachexia, catabolism or sarcopenia.
A pharmaceutical composition for resisting pasteurella multocida belongs to the technical field of pharmaceutical compositions. The invention aims to synthesize an antibacterial pharmaceutical composition for treating bovine pasteurella multocida infection by effectively combining three medicaments. The effective components of the invention are ciprofloxacin, thioridazine and tetracycline. The pharmaceutical composition has clinical effects of antibiosis, antiphlogosis and the like, can effectively treat the infection of the pasteurella multocida of cattle, and has high-efficiency bactericidal activity and can greatly reduce the dosage of medication, thereby greatly reducing the toxic and side effects of the medicine. The basic mechanism of the action of the medicine combination is as follows: the antibacterial agent has good antibacterial effect by inhibiting the outward transport pump of bacteria and the synthesis and replication of DNA. Further proves the clinical efficacy and safety of the medicine.
BACKGROUND: Psoriasis, a chronic inflammatory skin disease, is increasingly effectively managed with the targeted immunotherapy; however, long-term immunotherapy carries health risks, and loss of response. Therefore, we need to develop the alternative treatment strategies. Mesenchymal stem/stromal cell (M.S.C.) exosomes stand out for their remarkable immunomodulatory properties, gaining widespread recognition. This study investigated whether M.S.C. exosomes can reduce psoriasis-induced hyperplasia by inducing Transforming Growth Factor beta 2 (TGF-beta2) signaling.
METHODOLOGY: Exosomes were isolated from M.S.C.s by ultracentrifugation. Then, scanning electron microscopy was used for the morphology of exosomes. To ascertain the exosome concentration, the Bradford test was used. To ascertain the cellular toxicity of exosomes in Human Umbilical Vein Endothelial Cells ( H.U.V.E.C), an MTT experiment was then conducted. Real-time PCR was used to quantify TGF beta2 expression levels, whereas an ELISA immunosorbent assay was used to determine the protein concentration of TGF beta2.
RESULTS: In this study, the exosomes of 15-30 nm in size that were uniform, and cup-shaped were isolated. Moreover, the IC50 value for this Treatment was calculated to be 181.750 µg/ml. The concentration of TGF-β2 gene in the target cells significantly increased following Treatment with the exosomes. Furthermore, the expression level of the studied gene significantly increased due to the Treatment.
CONCLUSION: Upregulating the expression of TGF-β2 in psoriatic cells via TGF-β2 signaling is one way exosomes can help reduce hyperplasia.
The invention relates to the medicine technique field, in particular to a gene-vector material, which is nonionics-modified polymine, the preparation and application. As non-virus vector, PEI also has the disadvantages like big cytotoxicity. Although the biocompatible hydrophilic polymer such as polyethylene glycol, which is adopted to modify PEI, reduces the toxin, the transfection efficiency is reduced. The purpose of the invention is to provide a gene vector which is PEI-based, of small toxin and high transfection efficiency. The invention provides a polyethyleneimine modified by polyoxyethylene stearate, as well as the preparation and application. The modified polyethyleneimine shows lower cytotoxicity and higher transfection efficiency in vitro, so that the disadvantage of polyethyleneimine is overcome and the reliable technical support is provided for the wide application of polyethyleneimine.
Mucus-penetrating liposomal nanoparticles and methods of making and using thereof are described herein. The nanoparticles contain one or more lipids, one or more PEG-conjugated lipids, and optionally one or more additional materials that physically and/or chemically stabilize the particles. The nanoparticle have an average diameter of about 100 nm to about 300 nm, preferably from about 100 nm to about 250 nm, more preferably from about 100 nm to about 200 nm. The particles are mobile in mucus. The liposomes can further contain one or more therapeutic, prophylactic, and/or diagnostic agent to be delivered to a mucosal surface, such as the CV tract, the colon, the nose, the lungs, and/or the eyes. The liposomes can further contain one or more CEST agents to allow real time imaging of the particles in a live animal. The particles may also further contain an imaging agent, such as a fluorescent label.
Benign thyroid diseases are a common public health problem. It has been reported that thyroid diseases can affect Quality of Life (QoL), but this is not easy to be assessed. Therefore, a valid instrument is necessary. Such an instrument is Thyroid-related patient-reported outcomes questionnaire (ThyPRO). ThyPRO has been recently translated and validated in Greek language. The questionnaire consists of 85 items grouped in 14 scales concerning goiter, hypothyroidism, hyperthyroidism and eye symptoms, tiredness, cognitive impairment, anxiety, depression, emotional susceptibility, cosmetic complaints and impaired social, and daily and sex life, as well as overall quality of life.

A few studies have demonstrated that various thyroid therapies may improve some aspects of QoL. The aim of the present study is to address the impact of thyroidectomy in QoL in patients with benign thyroid diseases.
FIELD: biotechnology, molecular biology, genetic engineering. SUBSTANCE: for preparing protein C of alpha-antigen of Streptococcus group B or its functional derivative recombinant DNA molecule is used. This DNA encodes an antigen taken among the group: N, C, N-C, R x , N-R x , R x -C, N- R x -C and N-R 9 -C where N means 5'-flanking amino acid sequence and in R x  x means a whole number and represents number of repeating copies of sequence consisting of 82 amino acids; R 9  means amino acid sequence consisting of the combination of sequence R 9  with additionally partially repeating sequence. Functional derivative of antigen is taken among the group: N, C, R 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6 ,R 7 ,R 8 ,R 9 ,R 9  and R x  or N-C, N-R 1  before N-R x , or R 1 -C before R x -C, or N-R 1 -C before N- -R 9 -C and derivative comprises at least 10 repeating R-units. Recombinant DNA is able to express protein, its fragment or its derivative in bacterial cells being DNA nucleotide sequence can be linked with promoter operatively. Plasmid vector is used for expression of protein in cells. The use of invention allows preparing vaccine able to confer in patient immunity against infection causing by Streptococcus group B. Invention can be used for preparing conjugated vaccine able to produce immunity against infection of Streptococcus group B. EFFECT: improved preparing method of vaccine, valuable medicinal properties. 9 cl, 13 dwg
In a 2-year oral carcinogenicity study in rats, ticlopidine at daily doses of up to 100 mg/kg (610 mg/m ) was not tumorigenic. For a 70-kg person (1.73 m body surface area) the dose represents 14 times the recommended clinical dose on a mg/kg basis and two times the clinical dose on body surface area basis. In a 78-week oral carcinogenicity study in mice, ticlopidine at daily doses up to 275 mg/kg (1180 mg/m ) was not tumorigenic. The dose represents 40 times the recommended clinical dose on a mg/kg basis and four times the clinical dose on body surface area basis. 222

Ticlopidine was not mutagenic in the Ames test, the rat hepatocyte DNA-repair assay, or the Chinese-hamster fibroblast chromosomal aberration test; or in the mouse spermatozoid morphology test, the Chinese-hamster micronucleus test, or the Chinese-hamster bone-marrow-cell sister-chromatid exchange test. Ticlopidine was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg/day. in vitroin vivo
The invention relates to the field of biological medicine and discloses a health food and a preparation method thereof. The health food comprises the following substances by weight: 4 to 8 parts of wolfberry, 3 to 8 parts of chrysanthemum, 4 to 10 parts of haw, 2 to 6 parts of sharpleaf galangal fruit and 4 to 10 parts of white peony root. The health food is developed through combination of traditional Chinese medicine treatment based on syndrome differentiation and newest modern scientific research achievements. The invention also provides a preparation method for the health food. The health food provided by the invention can effectively improve asthenopia, enhance distant vision and duration of clear vision, is convenient, safe and reliable to eat, low in price, applicable to teenagers or people using computers for a long time and suitable for long-term eating, and incurs no adverse reaction. Equipment used in the preparation method is simple; cost is low; and industrial production can be realized.